恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响

目的 分析恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响。方法 选取2018年5月~2019年5月在我院治疗的乙肝肝硬化患者156例，采用随机分为对照组和观察组，各78例。对照组采用恩替卡韦治疗，观察组在对照组治疗基础上联合微生态制剂治疗，比较两组临床治疗前后肝功能指标、临床症状评分、肝纤维化指标及血清HBV-DNA转阴率。结果治疗后两组ALT、ALT、TBIL均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组乏力、厌食、腹胀评分低于对照组，差异有统计学意义（P＜0.05）；两组肝纤维化指标（HA、PC-Ⅲ、Ⅳ-C）均较治疗前改善，且观察组改善优于对照组，差异有统计学意义（P＜0.05）；治疗后两组门静脉内径和脾脏厚度均较治疗前降低，且观察组低于对照组，差异有统计学意义（P＜0.05）。结论 恩替卡韦联合微生态制剂治疗乙肝肝硬化患者，可改善临床患者症状、肝功能，具有理想的治疗效果，为改善患者预后提供有利的条件。

Effect of Entecavir Combined with Microecological Preparation on Liver Function and Prognosis in Patients with Hepatitis B Cirrhosis

Objective To analyze the effects of entecavir combined with microecological preparations on liver function and prognosis in patients with hepatitis B cirrhosis. Methods A total of 156 patients with hepatitis B cirrhosis who were treated in our hospital from May 2018 to May 2019 were randomly divided into control group and observation group, 78 cases each. The control group was treated with entecavir. The observation group was treated with microecological preparations on the basis of the control group. The liver function index, clinical symptom score, liver fibrosis index and serum HBV-DNA negative rate were compared before and after clinical treatment. Results After treatment, the levels of ALT, ALT and TBIL were lower than those before treatment, and the observation group was lower than the control group,the difference was statistically significant (P<0.05). The scores of fatigue, anorexia and abdominal distension in the observation group were lower than those in the control group,the difference was statistically significant (P<0.05). The liver fibrosis indexes (HA, PC-Ⅲ, Ⅳ-C) of the two groups were better than those before treatment, and the improvement of the observation group was better than that of the control group,the difference was statistically significant (P<0.05); after treatment, the portal vein diameter and spleen thickness of the two groups were lower than those before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). Conclusion Entecavir combined with microecological preparations for the treatment of patients with hepatitis B cirrhosis can improve the symptoms and liver function of clinical patients, and has an ideal therapeutic effect, which provides favorable conditions for improving the prognosis of patients.